Kardiovaskulyarnye aspekty deystviya polovykh gormonov i ikh klinicheskoe znachenie v postmenopauze

Cite item

Full Text


About the authors

I A Ilovayskaya


  1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Int Med 1976; 85: 447-52.
  2. Archer DF. Premature menopause increases cardiovascular risk. Climacteric 2009; 12 (Suppl. 1): 26-31.
  3. Rivera CM, Grossardt BR, Rhodes DJ et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16 (1): 15-23.
  4. Lapidus L, Bengtsson C, Lindquist O. Menopausal age and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study in Gothenburg, Sweden. Acta Obstet Gynecol Scand 1985 (Suppl. 130): 37-41.
  5. Lisabeth LD, Beiser AS, Brown DL et al. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 2009; 40 (4): 1044-9.
  6. Simoncini T, Mannella P, Fornari L et al. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004; 69 (8-9): 537-42.
  7. Fu XD, Simoncini T. Non-genomic sex steroid actions in the vascular system. Semin Reprod Med 2007; 25 (3): 178-86.
  8. Han G, Ma H, Chintala R et al. Essential role of the 90-kilodalton heat shock protein in mediating nongenomic estrogen signaling in coronary artery smooth muscle. J Pharmacol Exp Ther 2009; 329 (3): 850-5.
  9. Ijuin H, Douchi T, Oki T et al. The contribution of menopause to changes in body-fat distribution. J Obstet Gynaecol Res 1999; 25 (5): 367-72.
  10. Abdulnour J, Doucet E, Brochu M et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause 2012; 19 (7): 760-7.
  11. Cho GJ, Lee JH, Park HT et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause 2008; 15 (3): 524-9.
  12. Kilic S, Yilmaz N, Erdogan G et al. Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. Climacteric 2009; 8: 1-8.
  13. Ushioda M, Makita K, Takamatsu K et al. Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women. Horm Metab Res 2006; 38 (9): 581-6.
  14. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003; 88 (6): 2470-8.
  15. Nadal A, Alonso-Magdalena P, Soriano S et al. The pancreatic beta-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol 2009; 304 (1-2): 63-8.
  16. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6 (3): 180-5.
  17. Liu ML, Xu X, Rang WQ et al. Influence of ovariectomy and 17beta-estradiol treatment on insulin sensitivity, lipid metabolism and post-ischemic cardiac function. Int J Cardiol 2004; 97 (3): 485-93.
  18. Barros RP, Machado UF, Gustafsson JA. Estrogen receptors: new players in diabetes mellitus. Trends Mol Med 2006; 12 (9): 425-31.
  19. Miller VM, Jayachandran M, Hashimoto K et al. Estrogen, inflammation, and platelet phenotype. Gend Med 2008; 5 (Suppl. A): S91-S102.
  20. Xing D, Nozell S, Chen YF et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009; 29 (3): 289-95.
  21. Salpeter SR, Walsh JM, Ormiston TM et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8 (5): 538-54.
  22. Stevenson JC, Rioux JE, Komer L, Gelfand M. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric 2005; 8 (4): 352-9.
  23. Criqui MH, Suarez L, Barrett-Connor E et al. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988; 128 (3): 606-14.
  24. Psaty BM, Heckbert SR, Atkins D et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154 (12): 1333-9.
  25. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (7): 605-13.
  26. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33.
  27. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297 (13): 1465-77.
  28. Seed M, Knopp RH. Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy. Curr Opin Lipidol 2004; 15 (4): 459-67.
  29. Cushman M, Kuller LH, Prentice R et al. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292 (13): 1573-80.
  30. Bretler DM, Hansen PR, Abildström SZ et al. Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study. Br J Clin Pharmacol 2011; 71 (1): 105-15.
  31. Cagnacci A, Cannoletta M, Palma F et al. Menopausal symptoms and risk factors for cardiovascular disease in postmenopause. Climacteric 2012; 15 (2): 157-62.
  32. Szmuilowicz ED, Manson JE, Rossouw JE et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause 2011; 18 (6): 603-10.
  33. Gast GC, Pop VJ, Samsioe GN et al. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease. Menopause 2011; 18 (2): 146-51.
  34. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006; 12 (5): 483-97.
  35. Korljan B, Bagatin J, Kokić S et al. The impact of hormone replacement therapy on metabolic syndrome components in perimenopausal women. Med Hypotheses 2010; 74 (1): 162-3.
  36. Rossi R, Bursi F, Veronesi B et al. Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women. Maturitas 2004; 49 (4): 315-20.
  37. Canonico M, Oger E, Plu-Bureau G et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115 (7): 840-5.
  38. Rosano GM, Fini M. Comparative cardiovascular effects of different progestins in menopause. Int J Fertil Womens Med 2001; 46 (5): 248-56.
  39. Falkeborn M, Lithell H, Persson I et al. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial. Climacteric 2002; 5 (3): 240-8.
  40. Christodoulakos GE, Lambrinoudaki IV, Economou EV et al. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. J Cardiovasc Pharmacol 2006; 47 (4): 542-8.
  41. Hellgren M, Conard J, Norris L, Kluft C. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas 2009; 62 (3): 287-93.
  42. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 2007; 21 (1): 265-73.
  43. Mueck AO, Seeger H, Bühling KJ. Use of dydrogesterone in hormone replacement therapy. Maturitas 2009; 65 (Suppl. 1): S51-S60.
  44. Seeger H, Mueck AO. Effects of dydrogesterone on the vascular system. Gynecol Endocrinol 2007; 23 (Suppl. 1): 2-8.
  45. Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009; 12 (5): 445-53.
  46. Koledova VV, Khalil RA. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 2007; 5 (4): 777-89.
  47. Shuster LT, Rhodes DJ, Gostout BS et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010; 65 (2): 161-6.

Copyright (c) 2012 Ilovayskaya I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies